Press

2019-11-25

Kancera and partner revise the patent strategy for the HDAC project

This is a translation of a press release in Swedish published in Stockholm 2019-11-22 Kancera AB (Nasdaq First North Growth Market: KAN) and Grünenthal work together to develop HDAC inhibitors for the treatment of pain and inflammation. The companies...

Read More
2019-11-25

Kancera updates the clinical development plan for KAND567

This is a translation of a press release in Swedish published 2019-11-21 Kancera AB (Nasdaq First North Growth Market: KAN) today announces that the company intends to complete the final phase of the Phase Ib study of the drug...

Read More
2019-09-03

Kancera unveils preclinical findings for its lead compound, KAND567, at world’s largest cardiovascular conference

Kancera AB (Nasdaq First North: KAN) announces the first public presentation of data for KAND567, its fractalkine receptor antagonist, in preclinical models of cardiovascular disease and its predicted translation to humans at the European Society of Cardiology (ESC) Congress...

Read More
2019-08-26

Kancera develops the dosing strategy for KAND567 which means an added delay of the phase 1b study

Kancera today announces that a further developed dosing strategy is intended to be tested for the treatment with KAND567. The reason is that the modified intravenous dosing studied in the phase Ib study in August 2019 resulted in a...

Read More
2019-08-23

Interim report for the second quarter 2019, 1 January – 30 June 2019

Second quarter in brief 1 April – 30 June 2019 Net sales for the period (January to June) amounted to SEK 3,1 Million (0 Million) of which the second quarter contributed SEK 0 Million (0 Million). R&D costs for...

Read More
2019-08-19

Kancera provides an operational update and announces an issue of shares in accordance with the agreement with Global Corporate Finance

Kancera AB (Nasdaq First North: KAN) announces that the company's clinical Phase Ib study according to plan will start again today. The aim is to report the study in November 2019. Kancera also announces new financing through a third...

Read More
2019-07-15

Kancera completes the third and final installment for the Fractalkine project

Kancera today announces that the third installment for the Fractalkine project and KAND567 is carried out according to the acquisition agreement. The payment that was activated in connection with the ongoing Phase Ib study takes place through a new...

Read More
2019-06-28

Kancera provides operational update and announces issue of shares according to agreement with Global Corporate Finance

Kancera AB (Nasdaq First North: CAN) today announced that two patent applications within the fractalkine project are now entering international phase and that the agreement with US Global Corporate Finance (GCF) has been utilized for a second new issue...

Read More
2019-06-24

Kancera announces positive interim results and a minor delay in ongoing Phase Ib clinical study of KAND567

Kancera today announces positive interim results in the ongoing Phase Ib study of KAND567, which aims to study intravenous infusion of the drug candidate to healthy subjects. The first exploratory part of the study shows a good safety profile...

Read More
2019-06-04

Kancera announces start of clinical Phase Ib study of KAND567

The clinical Phase Ib study of intravenous administered KAND567 has started and is planned to be completed during the third quarter of 2019. KAND567 has previously been shown to be well tolerated and to have good pharmacokinetic properties when...

Read More